ClinicalTrials.gg
TerminatedNCT03381144Updated Oct 18, 2019

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants

A Phase 1 interventional study of GDC-0334 and Placebo in Healthy Volunteers, sponsored by Genentech, Inc.. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-18.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Why this study was terminated
Molecule development was terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single-center, three-part study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of single and multiple ascending doses of GDC-0334 and the effect of food on the pharmacokinetics of GDC-0334 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females. Females may be of non- or childbearing potential. Healthy females of childbearing potential must agree to use a highly effective method of .
  • Healthy males must agree to use an adequate method of contraception
  • of 18.0 to 32.0 kilograms per meter squared (kg/m\^2) or, if outside the range, considered not by the investigator
  • Must be willing and able to communicate and participate in the whole study

Exclusion criteria

Exclusion Criteria:

  • Participants who have received any medicinal product in a clinical research study within the previous 3 months
  • Participants who are study site employees, or immediate family members of a study site or sponsor employee
  • Participants who have previously been enrolled in this study. Participants who have enrolled in Part 1 are not permitted to enrol in Parts 2 or 3, and participants who have enrolled in Part 2 are not permitted to enroll in Part 3
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption >14 units per week (1 unit = ½ pint beer, 25 milliliters (mL) of 40% spirit or a 125-mL glass of wine)
  • Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 6 parts per million (ppm) at screening or admission
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  • abnormal biochemistry, hematology or urinalysis as judged by the investigator
  • Positive drugs-of-abuse test result at screening or admission
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab), or (HIV) results
  • Evidence of renal impairment at screening, as indicated by an estimated of \<70 milliliters per minute (mL/min) using the Cockcroft-Gault equation
  • History of seizure
  • History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder, as judged by the investigator
  • Participants with a history of cholecystectomy or gall stones (applies to any regimen where food effect is being explored)
  • History of serious adverse reaction or serious to any drug or the formulation
  • Presence or history of active allergy requiring treatment, as judged by the investigator. History of hayfever is allowed unless it is active.
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days or 5 half-lives, whichever is longer, before investigational medicinal product administration. Exceptions may apply on a case-by-case basis, if considered not to interfere with the objectives of the study, as agreed by the principal investigator and sponsor's medical monitor.
  • History or presence of an abnormal (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction, at screening or admission
  • corrected using Fridericia's formula (QTcF) > 450 milliseconds (msec) demonstrated by at least two ECGs >30 minutes apart
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome
  • Current treatment with medications that are well known to prolong the QT interval
  • History of dermatographism
  • Presence or history of clinically significant skin disorders, as judged by the investigator (Parts 1 and 3 only)
  • History of trauma or surgery (laceration repair is not excluded) to the arm but not including wrist or hand injury/surgery (Parts 1 and 3 only)
  • Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Part 1: GDC-0334

    Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.

    Drug: GDC-0334

  • Placebo comparator
    Part 1: Placebo

    Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.

    Drug: Placebo

  • Experimental
    Part 2: GDC-0334

    Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.

    Drug: GDC-0334

  • Placebo comparator
    Part 2: Placebo

    Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.

    Drug: Placebo

  • Experimental
    Part 3: GDC-0334

    Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.

    Drug: GDC-0334

  • Placebo comparator
    Part 3: Placebo

    Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.

    Drug: Placebo

Interventions

  • DrugGDC-0334

    Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.

  • DrugPlacebo

    Participants will receive GDC-0334-matching placebo.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events

    Time frame: From signing of informed consent until 30 days after the last dose of study drug (Up to approximately 42 days)

  2. Severity of Adverse Events, as Graded per the World Health Organization (WHO) Toxicity Grading Scale

    Time frame: From signing of informed consent until 30 days after the last dose of study drug (Up to approximately 42 days)

  3. Change from Baseline in Blood Pressure

    Time frame: Up to approximately 42 days

  4. Change from Baseline in Heart Rate

    Time frame: Up to approximately 42 days

  5. Incidence of Electrocardiogram (ECG) Abnormalities

    Time frame: Up to approximately 42 days

  6. Incidence of Clinical Laboratory Abnormalities

    Time frame: Up to approximately 30 days

  7. Incidence of Physical Examination Abnormalities

    Time frame: Up to approximately 42 days

  8. Incidence of Neurological Examination Abnormalities

    Time frame: Up to approximately 31 days

  9. Columbia-Suicide Severity Rating Scale (C-SSRS) - Part 3 Only

    Time frame: Up to approximately 42 days

Secondary outcomes

  1. Elapsed Time from Dosing at Which GDC-0334 is First Quantifiable in a Concentration versus Time profile (Tlag )

    Time frame: Up to approximately 35 days

  2. Time to Maximum Plasma Concentration (Tmax) for GDC-0334

    Time frame: Up to approximately 35 days

  3. Maximum Observed Plasma Concentration (Cmax) for GDC-0334

    Time frame: Up to approximately 35 days

  4. Concentration at 24 hours Post-dose (C24) for GDC-0334

    Time frame: Up to approximately 35 days

  5. Concentration at 12 hours Post-dose (C12) for GDC-0334

    Time frame: Up to approximately 35 days

  6. Area Under the Plasma Concentration Curve from Time Zero to the Last Measurable Concentration (AUC0-t) for GDC-0334

    Time frame: Up to approximately 35 days

  7. Area Under the Plasma Concentration Curve from Time Zero Extrapolated to Infinity (AUC0-inf) for GDC-0334

    Time frame: Up to approximately 35 days

  8. Percentage of AUC0-inf Accounted for by Extrapolation to Infinity (AUC%extrap) for GDC-0334

    Time frame: Up to approximately 35 days

  9. Apparent Terminal Elimination Half-Life (t1/2) for GDC-0334

    Time frame: Up to approximately 35 days

07

Study locations

1 site
  • Quotient Clinical Ltd, Clinical Research Unit
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Apr 2019, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 21, 2017
StartActual
Dec 8, 2017
Primary completionActual
Apr 29, 2019
CompletionActual
Apr 29, 2019
Last update
Oct 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03381144
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 21, 2017
Start date
Dec 8, 2017
Primary completion
Apr 29, 2019
Completion
Apr 29, 2019
Last update
Oct 18, 2019

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion